Phio Pharmaceuticals Corp. Cash Flow Statement
PHIO|7 years of annual SEC 10-K data (FY2012-FY2020)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Phio Pharmaceuticals Corp. used $9M in operating cash flow and negative free cash flow of $9M in FY2020.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.94 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|
| Net Income | -$8.9M | -$7.4M | -$12.5M | -$9.0M | -$10.2M | -$89.0K | -$89.0K |
| Depreciation & Amortization | $67.0K | $81.0K | $70.0K | $53.0K | $77.0K | $147.0K | $147.0K |
| Operating Cash Flow | -$8.6M | -$7.5M | -$9.5M | -$7.8M | -$7.3M | -$5.1M | -$5.1M |
| Capital Expenditures | $72.0K | $5.0K | $203.0K | $4.0K | $57.0K | $15.0K | $15.0K |
| Free Cash Flow | -$8.7M | -$7.5M | -$9.7M | -$7.8M | -$7.4M | -$5.1M | -$5.1M |
| FCF Margin | -41509.5% | -5452.9% | -64780.0% | -40863.2% | -21688.2% | -5234.0% | -5234.0% |